Acquisition strengthens EY’s Veeva Centers of Excellence, expanding clinical, regulatory, and commercial services for global pharma and biotech companies
mRNA-4359 advances to phase 2 following encouraging results in checkpoint inhibitor-resistant Melanoma
Acquisition includes OTX-201, an investigational next-generation CAR T-cell therapy designed to reprogram cells in vivo with potential best-in-class profile for autoimmune diseases
ExellenS applies optimized facility designs, equipment, and processes across all sites to ensure equivalency and speed
Merck will showcase results in innovative solutions in HIV treatment and prevention
The Court dismissed Swiss drugmaker Roche’s plea for interim injunction
First patients enrolled in Phase I trial with KQB548, an investigational KRAS inhibitor designed to treat KRAS G12D-mutated tumors
New gene expression profiling test enhances precision in assessing lung transplant rejection and injury
The initiative successfully demonstrates that used medical plastic packaging can be recycled and transformed back into new, contact-sensitive medical packaging
FineCross M3 empowers physicians to perform safer PCI procedures, helping improve outcomes in patients with challenging coronary anatomies
Subscribe To Our Newsletter & Stay Updated
